Skip to main content
Leukemia Research Reports logoLink to Leukemia Research Reports
. 2025 Jun 17;24:100519. doi: 10.1016/j.lrr.2025.100519

Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis

Magdalena Witkowska a,b,⁎, Mikołaj Malicki c, Weronika Marcinkowska c, Kacper Kościelny b,d, Adrianna Kowalik c, Damian Mikulski b,d, Grzegorz Mirocha c
PMCID: PMC12266480  PMID: 40672808

Abstract

With the introduction of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and radiation combined, the prognosis of Hodgkin lymphoma (HL) has significantly improved, with 5-year overall survival of around 90 %. While the lymphoma has become highly curable, the side effects of ABVD treatment are dire and warrant continuous review. Immune checkpoint inhibitors, including nivolumab, have demonstrated high therapeutic efficacy in relapsed and refractory HL patients. Nevertheless, despite much data, the therapy duration and long-term efficacy question remains unresolved. In this retrospective study, in a cohort of 10 patients, we observed a high complete response (CR) rate, while during long-term observation, 5 patients relapsed, and 3 had autoimmune treatment-related complications.

Keywords: Hodgkin lymphoma, Nivolumab, Anti-PD-1 agents, Immunotherapy, HL

1. Introduction

Hodgkin lymphoma (HL) is a rare B-cell malignant neoplasm that affects young adults and less frequently, elderly patients. It has been estimated that the overall incidence of HL in the European population is approximately 2–3 per 100.000 individuals [1]. Patients usually present with supra-diaphragmatic lymphadenopathy, often with high fever, drenching, night sweats, and profound weight loss (called “B” symptoms) [2]. HL is characterised by a variety of cells included in the tumor and its microenvironment. They include, among other things, large multinucleated cells derived from B-lymphocytes (Reed-Sternberg or Hodgkin cells) and numerous immune effectors cells. The classification is based on morphological and immunohistochemical features and includes classical Hodgkin lymphoma (cHL) and nodular lymphocyte predominant (NLPHL) [3]. Identifying the histological subtype and immune phenotype is an important prognostic factor and enables effective therapy [4].

HL is known as a highly curable malignancy with 5-year relative survival for patients diagnosed with cHL at age 0 – 19 years old 96.4 % and 89.8 % for those between 20 – 64 years old (based on 2007–2013 SEER data) [5]. Nowadays, 85 – 95 % of patients achieve complete remission (CR) thanks to a combination of conventional chemotherapy and radiotherapy. Nevertheless, there are still cases that exhibit progressive or relapsed disease [6]. Therefore, there is a need for further development of novel treatment strategies. Immunotherapy is currently a promising strategy for patients who did not respond to first-line treatment or experienced relapsed disease [7].

The Programmed Death 1 (PD-1) signalling system is the most important grip point for HL immunotherapy. The PD-1-mediated pathway is responsible for maintaining peripheral tolerance by restricting T lymphocytes' activation, proliferation, and effector functions [8]. Interestingly, cancers can express PD-1 ligands (PD-1L) on the surface of their cells and in this way evade a host immune response [9]. Tumours expressing PD-L1 have been reported to show good responses to anti-PD1 blockade [10]. Preliminary studies suggest that hematologic malignancies often reveal PD-1L expression and that it may be a potentially viable treatment target [[11], [12], [13], [14]]. HL is no exception; PD-1L is overexpressed in Reed-Sternberg cells [15]. Moreover, it has been reported that Ebstein-Barr virus (EBV) infection also induces the expression of PD-1L in HL [16]. Roemer et al. revealed that most HL cases exhibit genetic alterations in chromosome 9p24.1 which leads to elevated PD-1L profile [17]. Considering this, PD-1L is common in HL specimens, supporting the use of immune checkpoint inhibitors. The most common used anti-PD-1 antibodies are nivolumab (human monoclonal IgG4 antibody) and pembrolizumab [18].

In the present study, we assessed patients from the Hematology Clinic in Lodz who received nivolumab. We evaluated its effectiveness in relapsed and refractory (R/R) HL patients. Additionally, we observed the duration for which the treatment should be continued and when possible side effects might occur.

2. Materials and methods

2.1. Study population

We retrospectively analyzed 10 patients with R/R Hodgkin lymphoma hospitalized in Hematology Clinic in Lodz, between January 2018 and September 2024. Data were collected from the local medical records. Histopathological diagnosis was based on the WHO classification the 4th edition. The study was performed in accordance with the local ethics committee. Because of its retrospective character, the local committee's approval was not obtained prior to initiating the study. The collected data did not include any personally identifiable information; therefore, informed consent from the patients was not required.

2.2. Study design

Patient’s characteristics included: age, gender, symptoms, systemic involvement according to the Ann Arbor staging classification, type of treatment, response to applied treatment and side effects. All patients received nivolumab 240 mg i.v. every 2 weeks until disease progression or excessive toxic effects.

2.3. Statistical analyses

Categorical variables were expressed as frequencies and percentages. Continuous variables were presented as medians with an interquartile range (25–75 %). The Python “lifelines” package was used to generate the time-to-event plot.

3. Results

The study cohort included 10 patients, mainly men (70 %), with a median age of 28.6 years (25th-75th percentile, 23.2- 35.5). Four patients (40 %) presented with extranodal involvement. The median number of lines of treatment before nivolumab administration was 4 (25–75 %, 3–5). Most patients (80 %) underwent autologous stem cell transplantation (autoSCT) before nivolumab administration. The median IPS score was 3.2 points (25–75 %: 2.5 – 4.0). Baseline characteristics with laboratory findings are summarized in Table 1.

Table 1.

The baseline study group characteristics. Data are presented as frequencies (%) for nominal variables or medians with interquartile range (25–75 %) for continuous variables.

Variable N (10 = 100 %)
Sex
F 3 (30.0)
M 7 (70.0)
Age (years) 28.6 (23.2, 35.5)
Hb (g/dl) 11.3 (10.6, 12.8)
LDH (U/l) 239.0 (188.8, 289.5)
B2M (mg/l) 2.6 (2.2,3.4)
Albumin (g/dl) 4.0 (3.8,4.7)
CRP (mg/l) 90.6 (28.8,159.6)
Previous AHSCT
Yes 8 (80.0)
No 2 (20.0)

The median number of administered doses of nivolumab was 29 (25–75 %, 18–46). Among the study cohort, three patients (30 %) experienced autoimmune complications during nivolumab treatment: one patient presented with autoimmune thyroiditis, one patient developed immune thrombocytopenia (ITP), and one patient experienced interstitial pneumonia with autoimmune features (IPAF) and autoimmune hepatitis. All this patients discontinued treartment due to this toxicity. Overall, 7 patients (70 %) achieved CR, and 3 patients achieved PR. Eventually 5 (50 %) patients experienced disease progression (Fig. 1). Two patients were qualified for allogeneic stem cell transplantation (alloSCT) after nivolumab treatment, and one patient underwent alloSCT twice. Median progression-free survival (PFS) was 34.7 months (Fig. 2). 10 year OS from the diagnosis was 83 % (Fig. 3a) and 4 year OS from nivolumab treatment was 90 % (Fig. 3b).

Fig. 1.

Fig 1

Duration of responses during nivolumab treatment.

Fig. 2.

Fig 2

Kaplan–Meier plot of progression-free survival (PFS) in the study cohort.

Fig. 3.

Fig 3

A. Kaplan–Meier plot of overall survival (OS) in the study cohort from the diagnosis. B. Kaplan–Meier plot of overall survival (OS) in the study cohort since nivolumab treatment.

4. Discussion

Nivolumab is currently approved by the US Food and Drug Administration and the European Medicines Agency for treating adults with R/R cHL. Specifically including patients in whom standard treatments have failed, including autoSCT and brentuximab vedotin therapy, and those in whom three or more prior lines of treatment were not successful [19]. At 5-year follow-up, the Phase 2 CheckMate 205 trial demonstrated favourable median overall survival (OS) and safety profile of nivolumab after the failure of auto-SCT [19]. However, 38 % of patients enrolled in the trial eventually experienced disease progression or unacceptable side effects. Similar results were observed in our study, where, over a 40-month observation period, 40 % of treated patients had progressive disease. According to these results, nivolumab possibly should be considered only as a bridge to more aggressive therapy.

Consequently, many patients are eligible for alloSCT [[21], [22], [23]]. Forty-four patients proceeded to alloSCT after a median of 13 doses of nivolumab. The 6-month rate of disease progression was 7 % [19]. Meanwhile, a total of 57 patients received alloSCT after a median of 63 days. Among them, 51 % were in complete remission (CR) 2 years after transplantation [19]. In a retrospective analysis conducted by Bekoz et al. among 15 patients undergoing alloSCT, an objective response was achieved in 9 patients [24]. In our study, only two patients underwent alloSCT, one of whom underwent procedure twice. Other patients did not have the transplantation due to lack of patient consent (4 patients) or insufficient response to the treatment (4 patients). Similar results reported Martínez et al. demonstrated that alloSCT recipients had more favorable PFS and OS. Moreover, almost all patients who did not undergo SCT experience relapse or progression, especially in patients who did not achieve CR [19]. However, the potential use of nivolumab as a bridge to alloSCT remains controversial due to the potential risk of adverse effects, such as graft-versus-host disease (GVHD), steroid-requiring fever syndrome, encephalitis, and veno-occlusive liver disease [19,21].

There is still no consensus on how long treatment with nivolumab is safe. We already know from the literature that the majority of patients will experience side effects over time, which will hinder nivolumab treatment. In the literature [25]. The most common immune-mediated adverse events (AEs) were hypothyroidism/thyroiditis, rash and hepatitis. Pneumonitis [25] and hepatitis [26] were the most common treatment-related AEs (TRAEs) leading to discontinuation of therapy. Autoimmune thrombocytopenia and lymphopenia were noticed in nivolumab monotherapy in some research [27], however it rarely occurred. In the study, all patients were strictly monitored for adverse events (AEs) attributed to nivolumab therapy, especially autoimmune complications. In our study in among 10 patients who received nivolumab, 3 of them experienced some autoimmune complications and discontinued therapy which is related to refereed literature.

The optimal duration of nivolumab therapy remains uncertain. Clinical trials indicate that most cases show a partial response to nivolumab, which tends to diminish over time. The phase 2 CheckMate 205 trial suggests that patients who have achieved CR for at least one year may discontinue treatment and restart if disease progresses [20]. Fedorova et al. discontinued nivolumab in patients who achieved CR, and the median time to relapse was 11 months. Nivolumab was later restarted in 11 patients, with a median progression-free survival (PFS) of 16.5 months in this group [28]. In the literature, durable responses to nivolumab were observed in patients with both CR and partial remission (PR). Studies indicate that 1-year OS rates in patients with stable disease were similar to those in patients with CR and PR. This suggests that patients who have not received an objective treatment response may benefit clinically from nivolumab therapy [21]. A Japanese phase II study confirmed that nivolumab can successfully continue after progressive disease (PD). Seven patients continued nivolumab treatment with resolution of B symptoms [29].

In recent years, novel, highly active immunotherapies have significantly improved outcomes for patients with relapsed and refractory HL. The response to nivolumab treatment was initially robust in the majority of patients. Sustained benefits were observed across various patient populations, including those who were refractory after brentuximab vedotin and autoSCTbrentuksimab vedotin and (autoSCT). However, long-term treatment with anti-PD-1 agents may reduce drug efficacy and contribute to chemoresistance. Nivolumab used as a salvage treatment without any consolidation shows a markedly high relapse rate in retrospective analyses, including our own. A potential solution could be the combination of active novel drugs in chemo-free approaches, which may further enhance results in terms of efficacy and toxicity. The use of immunotherapies, including nivolumab, continues to grow and evolve, but more research and time are needed to determine their full utility and long-term effects in HL patients.

CRediT authorship contribution statement

Magdalena Witkowska: Conceptualization, Formal analysis, Methodology, Supervision. Mikołaj Malicki: Data curation. Weronika Marcinkowska: Data curation, Formal analysis. Kacper Kościelny: Validation, Visualization, Writing – review & editing. Adrianna Kowalik: Writing – original draft. Damian Mikulski: Data curation, Formal analysis. Grzegorz Mirocha: Resources, Software.

Declaration of competing interest

Authors declare no conflict of interest.

References

  • 1.National Cancer Institute Surveillance Epidemiology and End Results Program . SEER; 2021. Cancer Stat facts: Hodgkin lymphoma.https://seer.cancer.gov/statfacts/html/hodg.html [Google Scholar]
  • 2.Ansell S.M. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin. Proc. 2015;90:1574–1583. doi: 10.1016/j.mayocp.2015.07.005. [DOI] [PubMed] [Google Scholar]
  • 3.Swerdlow S.H., Campo E., Harris N.L., Jaffe ES., Pileri S.A., Stein H., Thiele J., Vardiman JW., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. Vol. 2. IARC; 2008. (WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues). [Google Scholar]
  • 4.Shanbhag S., Ambinder R.F. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J. Clin. 2018;68:116–132. doi: 10.3322/caac.21438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.National Cancer Institute Bethesda, MD: based on November 2016 SEER data submission, posted to the SEER web site, SEER. 2017. https://seer.cancer.gov/csr/1975_2014/ (April. (April)
  • 6.Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. 2020. [DOI] [PubMed] [Google Scholar]
  • 7.Steidl C., Connors J.M., Gascoyne R.D. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J. Clin. Oncol. 2011;29:1812–1826. doi: 10.1200/JCO.2010.32.8401. [DOI] [PubMed] [Google Scholar]
  • 8.Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008;26:677–704. doi: 10.1146/annurev.immunol.26.021607.090331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol. 2010;37:430–439. doi: 10.1053/j.seminoncol.2010.09.005. [DOI] [PubMed] [Google Scholar]
  • 10.Taube J.M., Klein A., Brahmer J.R., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014;20:5064–5074. doi: 10.1158/1078-0432.CCR-13-3271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Andorsky D.J., Yamada R.E., Said J. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin. Cancer Res. 2011;17:4232–4244. doi: 10.1158/1078-0432.CCR-10-2660. [DOI] [PubMed] [Google Scholar]
  • 12.Bielinski K., Puła B., Bołkun Ł. Checkpoint inhibitors as potential therapeutics in acute myeloid leukemia. Acta Haematol. Pol. 2024;55(6):343–353. [Google Scholar]
  • 13.Berger R., Rotem-Yehudar R., Slama G., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008;14:3044–3051. doi: 10.1158/1078-0432.CCR-07-4079. [DOI] [PubMed] [Google Scholar]
  • 14.Westin J.R., Chu F., Zhang M., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69–77. doi: 10.1016/S1470-2045(13)70551-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Yamamoto R., Nishikori M., Kitawaki T., et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111:3220–3224. doi: 10.1182/blood-2007-05-085159. [DOI] [PubMed] [Google Scholar]
  • 16.Green M.R., Rodig S., Juszczynski P., et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy [published correction appears in Clin Cancer Res. 2012 Apr 1; 18:2117] Clin. Cancer Res. 2012;18:1611–1618. doi: 10.1158/1078-0432.CCR-11-1942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Roemer M.G., Advani R.H., Ligon A.H., et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J. Clin. Oncol. 2016;34:2690–2697. doi: 10.1200/JCO.2016.66.4482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sharma P., Allison J.P. The future of immune checkpoint therapy. Science. 2015;348:56–61. doi: 10.1126/science.aaa8172. [DOI] [PubMed] [Google Scholar]
  • 19.Martínez C., Carpio C., Heras I., Ríos-Herranz E., Buch J., Gutierrez A., Romero S., Zeberio I., García-García I., Rodriguez-Izquierdo A., Alonso R., Bargay J., Barrenetxea C., Domingo-Doménech E., de Haro M.E., Palomera L., García-Sanz R., Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO) Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after Nivolumab therapy for relapse/refractory Hodgkin lymphoma: real-life experience in Spain. Biol. Blood Marrow Transplant. 2020;26(8):1534–1542. doi: 10.1016/j.bbmt.2020.02.003. AugEpub 2020 Feb 14. PMID: 32068094. [DOI] [PubMed] [Google Scholar]
  • 20.Ansell S.M., Bröckelmann P.J., von Keudell G., Lee H.J., Santoro A., Zinzani P.L., Collins G.P., Cohen J.B., de Boer J.P., Kuruvilla J., Savage K.J., Trněný M., Provencio M., Jäger U., Willenbacher W., Wen R., Akyol A., Mikita-Geoffroy J., Shipp M.A., Engert A., Armand P. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023 Oct 24;7(20):6266–6274. doi: 10.1182/bloodadvances.2023010334. PMID: 37530622; PMCID: PMC10589773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Armand P., et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the Multicohort single-arm Phase II CheckMate 205 trial. JCO. 2018;36:1428–1439. doi: 10.1200/JCO.2017.76.0793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Herbaux C., Gauthier J., Brice P., Drumez E., Ysebaert L., Doyen H., Fornecker L., Bouabdallah K., Manson G., Ghesquières H., Tabrizi R., Hermet E., Lazarovici J., Thiebaut-Bertrand A., Chauchet A., Demarquette H., Boyle E., Houot R., Yakoub-Agha I., Morschhauser F. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017 May 4;129(18):2471–2478. doi: 10.1182/blood-2016-11-749556. Epub 2017 Mar 7. PMID: 28270452. [DOI] [PubMed] [Google Scholar]
  • 23.Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., Schuster S.J., Millenson M.M., Cattry D., Freeman G.J., Rodig S.J., Chapuy B., Ligon A.H., Zhu L., Grosso J.F., Kim S.Y., Timmerman J.M., Shipp M.A., Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015;372(4):311–319. doi: 10.1056/NEJMoa1411087. Jan 22Epub 2014 Dec 6. PMID: 25482239; PMCID: PMC4348009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Bekoz H., Ozbalak M., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T.F., Altuntas F., Cakar M.K., Sonmez M., Gulbas Z., Demir N., Kaynar L., Yildirim R., Karadogan I., Arat M., Kapucu I., Aslan N.A., Ozkocaman V., Turgut M., Yuksel M.K., Ozcan M., Hacioglu S.K., Barista I., Demirkaya M., Saydam G., Toprak S.K., Yilmaz M., Demirkol O., Ferhanoglu B. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann. Hematol. 2020;99(11):2565–2576. doi: 10.1007/s00277-020-04077-4. NovEpub 2020 Jun 7. PMID: 32507911. [DOI] [PubMed] [Google Scholar]
  • 25.Ansell S.M., Bröckelmann P.J., Keudell G., Lee H.J., Santoro A., Zinzani P.L., Collins G.P., Cohen J.B., Boer J.P., Kuruvilla J., Savage K.J., Trněný M., Provencio M., Jäger U., Willenbacher W., Wen R., Akyol A., Mikita-Geoffroy J., Shipp M.A., Engert A., Armand; P. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023;7(20):6266–6274. doi: 10.1182/bloodadvances.2023010334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Armand P., Engert A., Younes A., Fanale M., Santoro A., Zinzani P.L., Timmerman J.M., Collins G.P., Ramchandren R., Cohen J.B., De Boer J.P., Kuruvilla J., Savage K.J., Trneny M., Shipp M.A., Kato K., Sumbul A., Farsaci B., Ansell S.M. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the Multicohort single-arm Phase II CheckMate 205 trial. J. Clin. Oncol. 2018 May 10;36(14):1428–1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. Erratum in: J Clin Oncol. 2018 Sep 10;36(26):2748. PMID: 29584546; PMCID: PMC6075855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Mei M.G., Lee H.J., Palmer J.M., Chen R., Tsai N.-C., Chen Lu, McBride K., Lynne Smith D., Melgar I., Song J.Y., Bonjoc K.-J., Armenian S., Nwangwu M., Lee P.P., Zain J., Nikolaenko L., Popplewell L., Nademanee A., Chaudhry A., Rosen S., Kwak L., Forman S.J., Herrera A.F. Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022;139(25):3605–3616. doi: 10.1182/blood.2022015423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Fedorova L.V., Lepik K.V., Mikhailova N.B., Kondakova E.V., Zalyalov Y.R., Baykov V.V., Babenko E.V., Kozlov A.V., Moiseev I.S., Afanasyev B.V. Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma. Ann. Hematol. 2021 Mar;100(3):691–698. doi: 10.1007/s00277-021-04429-8. [DOI] [PubMed] [Google Scholar]
  • 29.Maruyama D., Terui Y., Yamamoto K., Fukuhara N., ChoiI K.J., Ando K., Hattori A., Tobinai K. Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Jpn. J. Clin. Oncol. 2020 Oct 22;50(11):1265–1273. doi: 10.1093/jjco/hyaa117. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Leukemia Research Reports are provided here courtesy of Elsevier

RESOURCES